BLA 125559 · Regeneron Pharmaceuticals
Praluent
Alirocumab · Injection · PCSK9 Inhibitor
NovelOrphanLast checked: Nov 20, 2026Latest source record: Oct 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Jul 24, 2015
Approved uses
9
Original approval plus efficacy supplements
Registered trials
97
35 Phase 3, 14 recruiting
FAERS reports
25,752
6,952 serious, 511 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 16, 2026.
PRALUENT ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death, myocardial infarction, stroke, or unstable angina requiring hospitalization) in adults at increased risk for these events . As an adjunct to diet and exercise to reduce low- density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). adults with homozygous familial hypercholesterolemia (HoFH). PRALUENT is a proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death, myocardial infarction, stroke, or unstable angina requiring hospitalization) in adults at increased risk for these events. ( 1 ) As an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in : adults with hypercholesterolemia ( 1 ) adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). ( 1 ) adults with homozygous familial hypercholesterolemia (HoFH). ( 1 )
Mechanism: Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (LDL) receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 9, 2025 Supplement 47 · Efficacy OrphanLabelLetter
- Mar 8, 2024 Supplement 39 · Efficacy OrphanLabelLetter
- Apr 1, 2021 Supplement 29 · Efficacy OrphanLabelLetter
- Apr 26, 2019 Supplement 20 · Efficacy LabelLetter
- Apr 26, 2019 Supplement 19 · Efficacy LabelLetter
- Aug 22, 2018 Supplement 14 · Efficacy LabelLetterReview
- Sep 20, 2017 Supplement 6 · Efficacy LabelLetter
- Apr 24, 2017 Supplement 1 · Efficacy LabelLetter
- Jul 24, 2015 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewLetter
2 products under this application
- PRALUENT · ALIROCUMAB 75MG · INJECTABLE, INJECTION · Prescription
- PRALUENT · ALIROCUMAB 150MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Alirocumab" as an intervention, any sponsor and status, largest first.
- ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With AlirocumabPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01663402 · 18,924 participants · Start Oct 2012 · Primary completion Jan 23, 2018
Drug: Alirocumab; Placebo and 1 more · For: Atherosclerotic Cardiovascular Disease
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,388 sites in all
- Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01507831 · 2,341 participants · Start Jan 2012 · Primary completion Nov 2014
Drug: Placebo (for alirocumab); Alirocumab and 1 more · For: Hypercholesterolemia
Sites: Huntsville, Alabama; Gilbert, Arizona; Sierra Vista, Arizona · 320 sites in all
- Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to PlaceboPivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT02957682 · 2,176 participants · Start Nov 2, 2016 · Primary completion Mar 5, 2020
Drug: Praluent (Alirocumab); Placebo · For: Hypercholesterolemia
Sites: Auburn, Alabama; Birmingham, Alabama; Mobile, Alabama · 188 sites in all
- Long Term Safety Study of PRALUENTTerminated
Regeneron PharmaceuticalsRegeneron (REGN)
NCT03694197 · 1,389 participants · Start Sep 28, 2018 · Primary completion Apr 8, 2020
Drug: Praluent · For: Heterozygous Familial Hypercholesterolemia; Non-familial Hypercholesterolemia
Sites: Auburn, Alabama; Mobile, Alabama; Beverly Hills, California · 123 sites in all
- PCSK9 Inhibitor on ACS Patients With Multivessel Disease and Relatively Low LDL-C Level in Chinese PopulationPivotal-lookingStatus unknown
Second Xiangya Hospital of Central South UniversityAcademic, hospital or other
NCT05043740 · 1,360 participants (planned) · Start Oct 2021 · Primary completion Oct 1, 2023
Drug: Repatha or Praluent · For: Acute Coronary Syndrome
- Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02476006 · 998 participants · Start Jun 23, 2015 · Primary completion Apr 12, 2019
Drug: ALIROCUMAB SAR236553 (REGN727); placebo (for injection training only) and 4 more · For: Hypercholesterolemia
Sites: Graz, Austria; Innsbruck, Austria; Linz, Austria · 153 sites in all
- Open Label Study of Long Term Safety Evaluation of AlirocumabPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01954394 · 986 participants · Start Dec 17, 2013 · Primary completion Jun 30, 2017
Drug: Alirocumab; Lipid-Modifying Therapy (LMT) · For: Hypercholesterolemia
Sites: Huntsville, Alabama; Tempe, Arizona; Bell Gardens, California · 177 sites in all
- Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)Pivotal-lookingCompleted
Regeneron PharmaceuticalsRegeneron (REGN)
NCT01926782 · 803 participants · Start Sep 2013 · Primary completion Sep 2014
Drug: Placebo (for alirocumab); Alirocumab and 1 more · For: Hypercholesterolemia
Sites: Chandler, Arizona; Goodyear, Arizona; Carmichael, California · 83 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myalgia1,710
- injection site pain1,406
- product dose omission1,363
- muscle spasms1,209
- arthralgia1,088
- fatigue1,054
- pain979
- pain in extremity959
- product dose omission issue926
- injection site bruising905
- diarrhoea833
- headache823
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2015 | 297 |
| 2016 | 2,738 |
| 2017 | 3,158 |
| 2018 | 4,179 |
| 2019 | 4,511 |
| 2020 | 2,093 |
| 2021 | 1,741 |
| 2022 | 1,662 |
| 2023 | 1,583 |
| 2024 | 1,364 |
| 2025 | 1,110 |
| 2026 | 1,315 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, et al. · N Engl J Med 2018 · Multicenter Study, Randomized Controlled Trial
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.
Räber L, Ueki Y, Otsuka T, et al. · JAMA 2022 · Randomized Controlled Trial
- Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG, Farnier M, Krempf M, et al. · N Engl J Med 2015 · Comparative Study, Multicenter Study
- Network Meta-Analysis of Randomized Trials Evaluating the Comparative Efficacy of Lipid-Lowering Therapies Added to Maximally Tolerated Statins for the Reduction of Low-Density Lipoprotein Cholesterol.
Toth PP, Bray S, Villa G, et al. · J Am Heart Assoc 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Lipoprotein(a) reduction with inclisiran, alirocumab, evolocumab, enlicitide, and lerodalcibep: A systematic review and meta-analysis of randomized controlled trials.
Mulligan MD, Gandhi RS, Vishwakarma R, et al. · J Clin Lipidol 2026 · Systematic Review, Meta-Analysis
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Bittner VA, Szarek M, Aylward PE, et al. · J Am Coll Cardiol 2020 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Regeneron
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.